Atherosclerosis Drug Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2029
Overview
Atherosclerosis Drug Market is expected to reach US$ 2.13 Bn. at a CAGR of 2.2% during the forecast period 2029.
The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.
The scope of the report includes a detailed study of global and regional markets for atherosclerosis drug with the reasons given for variants in the growth of the industry in certain regions. The market growth is attributed to an upsurge in the aging population and enhancement in frequency of heart attacks due to atherosclerosis. Similarly, Obesity, unhealthy diets, and changes in lifestyles are factors leading to cardiovascular diseases. In addition, availability of new remedial approaches are drive global atherosclerosis drug market.
Government participation has also played an important role in raising concerns and creating awareness about cardiovascular disease, improving the quality of healthcare services and infrastructure, which has been encouraging pharmaceutical companies to develop effective drugs for the treatment of various diseases. These factors are projected to boost the global atherosclerosis drug market. However, dependence on symptom-based therapy in numerous cases, inefficiency and adverse effects (increased incidence of diabetes and hemorrhagic stroke) of drugs existing in the market are anticipated to restrain the global atherosclerosis drug market during forecast period.
To know about the Research Methodology:- Request Free Sample Report
The report on global atherosclerosis drug market covers segments such as drug type, medication, distribution channel and region. The drug type segment includes statins, fibrates, vitamins and other drugs. Among the drug type, statins is accounted for the largest xx% market share in the global atherosclerosis drug market, because statins are a class of drugs often prescribed by doctors to help lower cholesterol levels in the blood. Also, it lowers the cholesterol levels and they help prevent heart attacks and stroke immediately.
The medication segment is further sub-segmented into anti-platelet medications, cholesterol lowering medications, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, water pills, diuretics, and others. Amongst them cholesterol lowering medications is accounted for the largest xx% market share in the global atherosclerosis drug market, because cholesterol lowering drugs include statins and fibrates. Based on distribution channel, the global atherosclerosis therapeutics market is sub-segmented into drug stores, hospital pharmacies, retail pharmacies, online pharmacies and clinics. Amongst them hospital pharmacies is accounted for the largest xx% market share in the global atherosclerosis drug market.
Based on regional segment, the global atherosclerosis therapeutics market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. In terms of revenue, North America and Europe are leading the atherosclerosis drug market in 2022. Rise in treatment rate, upsurge in remedy options among the aging population, and enhanced number of aging population worldwide are the key drivers of the market. Government’s participation and support for R&D’s of pharmaceutical and biotechnology companies for the development of new treatment is also impacting the growth of the market in North America and Europe. Additionally, Asia Pacific is projected to witness noteworthy growth in the market, due to increased number of key players in this region.
Key players operating in the global atherosclerosis therapeutics market are Pfizer, Inc., GlaxoSmithKline Plc., Sanofi, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Novartis AG, Merck & Co., Inc., Bayer AG, Mylan N.V., Amgen Inc., Ionis Pharmaceuticals, Inc., Anthera Pharmaceuticals, Cardium Therapeutics, and The Medicine Company.Pfizer, Inc. is lead global market for atherosclerosis drug. The leading position of the Pfizer, Inc. Company is attributed to its robust distribution channel portfolio which comprises traditional as well as innovative technology platforms that help reorganize atherosclerosis drug. The company’s extensive presence across the globe has also played an important role in securing its position in the atherosclerosis drug market. The report covers recent developments in the global atherosclerosis drug market such as in December, 2021, Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline; the British company will maintain a controlling share.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global atherosclerosis drug market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Distribution Channel, price, financial position, Distribution Channel portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the global atherosclerosis drug market.
Global Atherosclerosis Drug Market Scope: Inquire before buying
| Global Atherosclerosis Drug Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 1.82 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 2.2% | Market Size in 2029: | US $ 2.13 Bn. |
| Segments Covered: | by Drug Type | Statins Fibrates Vitamins Other Drugs |
|
| by Medication | Cholesterol Lowering Medications Beta Blockers Angiotensin-converting enzyme (ACE) Inhibitors Calcium Channel blockers Water Pills Diuretics Antiplatelet Medications Other Medications |
||
| by Distribution Channel | Drug Stores Hospital Pharmacies Retail Pharmacies Online Pharmacies Clinics |
||
Atherosclerosis Drug Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Atherosclerosis Drug Market, Key Players are:
1.Pfizer, Inc.
2.GlaxoSmithKline Plc
3.Sanofi, F. Hoffmann-La Roche Ltd
4.Janssen Pharmaceuticals, Inc.
5.Novartis AG
6.Merck & Co., Inc.
7.Bayer AG
8.Mylan N.V., Amgen Inc.
9.Ionis Pharmaceuticals, Inc.
10.Anthera Pharmaceuticals
11.Cardium Therapeutics
12.The Medicine Company
13.AstraZeneca
14.Merck & Co., Inc.
15.Eli Lilly and Company
16.Amgen Inc
Frequently Asked Questions:
1. Which region has the largest share in Global Atherosclerosis Drug Market?
Ans: North America region held the highest share in 2022.
2. What is the growth rate of Global Atherosclerosis Drug Market?
Ans: The Global Market is growing at a CAGR of 2.13% during forecasting period 2023-2029.
3. What is scope of the Global Atherosclerosis Drug market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Atherosclerosis Drug market?
Ans: The important key players in the Global Market are – Pfizer, Inc., GlaxoSmithKline Plc, Sanofi, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Novartis AG, Merck & Co., Inc., Bayer AG, Mylan N.V., Amgen Inc., Ionis Pharmaceuticals, Inc., Anthera Pharmaceuticals, Cardium Therapeutics, The Medicine Company, AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, and Amgen Inc
5. What is the study period of this market?
Ans: The Global Atherosclerosis Drug Market is studied from 2022 to 2029.